Want to see NVCR full AI Analyst Report?
NVCR Stock Chart & Stats
$17.65
-$2.34(-11.71%)
At close: 4:00 PM EDT
$17.65
-$2.34(-11.71%)
Day’s Range― - ―
52-Week Range$9.82 - $21.45
Previous CloseN/A
Volume3.88M
Average Volume (3M)1.89M
Market Cap
$1.90B
Enterprise Value$1.54K
Total Cash (Recent Filing)$440.56M
Total Debt (Recent Filing)$233.42M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Oct 22, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding116,445,840
10 Day Avg. Volume2,096,710
30 Day Avg. Volume1,887,454
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)4.23
Price to Sales (P/S)2.20
P/FCF Ratio-19.05
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$25.83Price Target Upside46.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.25
Revenue Forecast (FY)$725.79M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsNovoCure’s mid‑70s gross margins reflect a high‑margin device plus consumables model and recent manufacturing/efficiency gains. Durable margins support funding of launches and R&D, improve operating leverage as revenue scales, and materially aid the path toward sustained profitability.
Recurring Revenue & Patient GrowthA recurring revenue model tied to ongoing therapy and consumable usage creates durable revenue visibility. Growing active patient counts (Optune Gio +11% YoY) indicate expanding adoption, which supports predictable top‑line, better unit economics over time, and scalability of margins.
Improved Leverage & Cash BufferDeclining debt and a meaningful cash balance give the company financial flexibility to fund commercialization and selected clinical programs without immediate capital raises. Improved leverage reduces refinancing risk and supports strategic optionality during multi‑year launches and trials.
Bears Say
Persistent Losses & Negative FCFDespite progress, sustained GAAP losses and negative free cash flow strain long‑term returns and limit reinvestment capacity. Continued cash burn requires disciplined execution or external funding if growth or margin improvements stall, increasing dilution or refinancing risk over the medium term.
Reimbursement & Access ConstraintsFragmented reimbursement and contracting create structural barriers to broad, consistent uptake outside core markets. Country‑by‑country access requirements slow commercialization, add selling complexity, and make revenue growth uneven and sensitive to local policy changes over the next several quarters.
Clinical Uncertainty & Trial RisksClinical trial setbacks and protocol redesigns introduce lasting uncertainty around label expansions and guideline adoption. Missed endpoints or altered trial footprints can delay approvals, limit new‑indication revenue, and raise execution risk for combinations and market expansion efforts over multiple quarters.
NovoCure News
NVCR FAQ
What was NovoCure Ltd.’s price range in the past 12 months?
NovoCure Ltd. lowest stock price was $9.82 and its highest was $21.45 in the past 12 months.
What is NovoCure Ltd.’s market cap?
NovoCure Ltd.’s market cap is $1.90B.
When is NovoCure Ltd.’s upcoming earnings report date?
NovoCure Ltd.’s upcoming earnings report date is Oct 22, 2026 which is in 83 days.
How were NovoCure Ltd.’s earnings last quarter?
NovoCure Ltd. released its earnings results on Jul 23, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.332 by $0.202.
Is NovoCure Ltd. overvalued?
According to Wall Street analysts NovoCure Ltd.’s price is currently Undervalued.
Does NovoCure Ltd. pay dividends?
NovoCure Ltd. does not currently pay dividends.
What is NovoCure Ltd.’s EPS estimate?
NovoCure Ltd.’s EPS estimate is -0.25.
How many shares outstanding does NovoCure Ltd. have?
NovoCure Ltd. has 116,445,840 shares outstanding.
What happened to NovoCure Ltd.’s price movement after its last earnings report?
NovoCure Ltd. reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.332. Following the earnings report the stock price went up 28.388%.
Which hedge fund is a major shareholder of NovoCure Ltd.?
Currently, no hedge funds are holding shares in NVCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovoCure Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.83 (46.36% Upside)
$25.83 (46.36% Upside)
Blogger Sentiment
Bullish
NVCR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 38.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 6.6%
Last 30 Days ▼ 6.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.74%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-36.17%
Trailing 12-Months
Company Description
NovoCure Ltd.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
NVCR Company Deck
NVCR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial commercial momentum highlighted by record net revenue (+16% YoY), active patient growth (Optune Gio +11% YoY), successful early launches (Optune Pax and Optune Lua), and a return to positive adjusted EBITDA in the quarter. Management also emphasized disciplined cost-management actions (R&D reductions and LUNAR-2 optimization) and updated full-year guidance reflecting confidence in continued progress. Key challenges include reimbursement and contracting hurdles (EU and Japan), reliance on some one-time benefits in Q2, the need to convert one-time prescribers into repeat prescribers for sustained growth, and clinical trial redesign risks. Overall, the positives — stronger commercial performance, profitability trajectory, regulatory milestones and clear launch progress — meaningfully outweigh the identified lowlights.View all NVCR earnings summariesNVCR Net revenue Breakdown
68.67% U.S.
11.82% Germany
8.74% Japan
6.22% Other EMEA
4.56% Greater China
NVCR Stock 12 Month Forecast
Average Price Target
$25.83
▲(46.36% Upside)
Technical Analysis
Ownership Overview
2.72% Insiders
22.46% Mutual Funds
0.22% Other Institutional Investors
57.96% Public Companies and
Individual Investors